ReviewOrphanet journal of rare diseases2018
An overview of the impact of rare disease characteristics on research methodology.
Review in Orphanet journal of rare diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- A Systematic Review of Cognition in Cervical Dystonia.Neuropsychology review · 2024Pooled it
- Neutral theory: applicability and neutrality of clinical study endpoints where a disease-specific instrument is available.BMC medical research methodology · 2023Pooled it
- Dental Implants in People with Osteogenesis Imperfecta: A Systematic Review.International journal of environmental research and public health · 2022Pooled it
- Necessity of Prophylactic Extrapleural Chest Tube During Primary Surgical Repair of Esophageal Atresia: A Systematic Review and Meta-Analysis.Frontiers in pediatrics · 2022Pooled it
- National registry for amyotrophic lateral sclerosis: a systematic review for structuring population registries of motor neuron diseases.BMC neurology · 2021Pooled it
- Characterizing health state utilities associated with Duchenne muscular dystrophy: a systematic review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2020Pooled it
- Trial
- Randomized controlled trial data for successful new drug application for rare diseases in the United States.Orphanet journal of rare diseases · 2023Trial
- Bayesian Dynamic Borrowing to Enhance Evidence for New Therapies.PharmacoEconomics · 2026Review
- Real World Data and Its Impact on the Management of Plasma Cell Dyscrasias.Current hematologic malignancy reports · 2026Review
- Decentralized rare disease studies in Germany: first results and hurdles of secondary use of patient data.BMC medical informatics and decision making · 2026Article
- Progressive myoclonus epilepsy in Down syndrome with Alzheimer's disease: An 11-year longitudinal study and proposed diagnostic red flags.Epilepsia open · 2026Article
- Using Latent Representations to Link Disjoint Longitudinal Data for Mixed-Effects Regression.Statistics in medicine · 2026Article
- Patients' and Providers' Attitudes Toward Artificial Intelligence and Electronic Health Record Use in Deep Phenotyping and Rare-Disease Screening: An Empty Systematic Review.Healthcare (Basel, Switzerland) · 2026Review
- Therapeutic hypothermia at 35 weeks' gestation: navigating controversy between randomized evidence, real-world practice, and shared decision-making.Pediatric research · 2026Article
- Air pollution and mortality in a University of Michigan amyotrophic lateral sclerosis cohort: a survival analysis.Environmental health : a global access science source · 2026Article
- Comparing disease burden of rare diseases with common medical conditions in china: evidence from a national online health survey in 2022.Archives of public health = Archives belges de sante publique · 2026Article
- Using a participation monitoring database to enhance recruitment in a rare cancer population.Journal of clinical and translational science · 2026Article
- From potential to podium: what we still don't know about talent identification and development in Para athletics, a scoping review.Frontiers in sports and active living · 2026Review
- New pharmacotherapies for the erythropoietic protoporphyrias: an analysis of trial protocols from a patient perspective.Orphanet journal of rare diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAbout 30 million individuals in the United States are living with a rare disease, which by definition have a prevalence of 200,000 or fewer cases in the United States ([National Organization for Rare Disorders], [About NORD], [2016]). Disease heterogeneity and geographic dispersion add to the difficulty of completing robust studies in small populations. Improving the ability to conduct research on rare diseases would have a significant impact on population health. The purpose of this paper is to raise awareness of methodological approaches that can address the challenges to conducting robust research on rare diseases. APPROACH: We conducted a landscape review of available methodological and analytic approaches to address the challenges of rare disease research. Our objectives were to: 1. identify algorithms for matching study design to rare disease attributes and the methodological approaches applicable to these algorithms; 2. draw inferences on how research communities and infrastructure can contribute to the efficiency of research on rare diseases; and 3. to describe methodological approaches in the rare disease portfolio of the Patient-Centered Outcomes Research Institute (PCORI), a funder promoting both rare disease research and research infrastructure.
resultsWe identified three algorithms for matching study design to rare disease or intervention characteristics (Gagne, et.al, BMJ 349:g6802, 2014); (Gupta, et.al, J Clin Epidemiol 64:1085-1094, 2011); (Cornu, et. al, Orphet J Rare Dis 8:48,2012) and summarized the applicable methodological and analytic approaches. From this literature we were also able to draw inferences on how an effective research infrastructure can set an agenda, prioritize studies, accelerate accrual, catalyze patient engagement and terminate poorly performing studies. Of the 24 rare disease projects in the PCORI portfolio, 11 are randomized controlled trials (RCTs) using standard designs. Thirteen are observational studies using case-control, prospective cohort, or natural history designs. PCORI has supported the development of 9 Patient-Powered Research Networks (PPRNs) focused on rare diseases.
conclusionMatching research design to attributes of rare diseases and interventions can facilitate the completion of RCTs that are adequately powered. An effective research infrastructure can improve efficiency and avoid waste in rare disease research. Our review of the PCORI research portfolio demonstrates that it is feasible to conduct RCTs in rare disease. However, most of these studies are using standard RCT designs. This suggests that use of a broader array of methodological approaches to RCTs --such as adaptive trials, cross-over trials, and early escape designs can improve the productivity of robust research in rare diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.